{"id":38669,"date":"2022-06-06T09:49:05","date_gmt":"2022-06-06T09:49:05","guid":{"rendered":"https:\/\/harchi90.com\/rare-biomarker-leads-to-unprecedented-results-in-small-rectal-cancer-study-endpoints-news\/"},"modified":"2022-06-06T09:49:05","modified_gmt":"2022-06-06T09:49:05","slug":"rare-biomarker-leads-to-unprecedented-results-in-small-rectal-cancer-study-endpoints-news","status":"publish","type":"post","link":"https:\/\/harchi90.com\/rare-biomarker-leads-to-unprecedented-results-in-small-rectal-cancer-study-endpoints-news\/","title":{"rendered":"Rare biomarker leads to &#8216;unprecedented&#8217; results in small rectal cancer study &#8211; Endpoints News"},"content":{"rendered":"<div>\n<p>In an ongoing, 18-person study, every single patient that has completed treatment saw their rectal cancer completely disappear.<\/p>\n<p>None of them needed chemotherapy, radiation, or surgery &#8211; the combination that makes up the standard of care for rectal cancer.<\/p>\n<p>Instead, the patients were treated with a six-month course of dostarlimab, the PD-1 antibody marketed as Jemperli that GSK acquired when it bought Tesaro in 2018. The prerequisite for receiving Jemperli, however, was that patients had early-stage, localized rectal cancer with a rare biomarker known as mismatch repair-deficient (MMR-deficient).<\/p>\n<div class=\"epn_limit\">\n    <\/p>\n<h3>Keep reading Endpoints with a free subscription<\/h3>\n<p>  Unlock this story instantly and join 143,300+ biopharma pros reading Endpoints daily &#8211; and it&#8217;s free. <\/p>\n<p>\n        <button type=\"button\" class=\"epn_ux_button epn_more epn_gate_sign_up_button\" data-toggle=\"modal\" data-target=\"#epn_subscribe_modal\">SIGN UP<\/button><br \/>\n        <button type=\"button\" class=\"epn_ux_button epn_more epn_gate_log_in_button\" data-toggle=\"modal\" data-target=\"#epn_sign_in_modal\">LOG IN<\/button>\n    <\/p>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>In an ongoing, 18-person study, every single patient that has completed treatment saw their rectal cancer completely disappear. None of them needed chemotherapy, radiation, or surgery &#8211; the combination that makes up the standard of care for rectal cancer. Instead, the patients were treated with a six-month course of dostarlimab, the PD-1 antibody marketed as &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/harchi90.com\/rare-biomarker-leads-to-unprecedented-results-in-small-rectal-cancer-study-endpoints-news\/\"> <span class=\"screen-reader-text\">Rare biomarker leads to &#8216;unprecedented&#8217; results in small rectal cancer study &#8211; Endpoints News<\/span> Read More &raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","spay_email":"","jetpack_publicize_message":"","jetpack_is_tweetstorm":false,"jetpack_publicize_feature_enabled":true},"categories":[8],"tags":[],"jetpack_featured_media_url":"","jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"fifu_image_url":"https:\/\/endpts.com\/wp-content\/uploads\/2020\/12\/GlaxoSmithKline-GSK-social-shutterstock-scaled.jpg","_links":{"self":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts\/38669"}],"collection":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/comments?post=38669"}],"version-history":[{"count":0,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/posts\/38669\/revisions"}],"wp:attachment":[{"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/media?parent=38669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/categories?post=38669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/harchi90.com\/wp-json\/wp\/v2\/tags?post=38669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}